"We consider it to be a promising marker: it will maybe be possible to use it to determine which patients with breast cancer require particularly close surveillance. More research, however, will be required in order to confirm our results before analysis of the protein can be used in the clinic", says Elin Karlsson.

Full bibliographic information:

I Karlsson E., Danielsson A., Delle U., Olsson B., Karlsson P., Helou K. Chromosomal changes associated with clinical outcome in lymph nodenegative breast cancer Cancer Genetics and Cytogenetics 2007;172(2):139-46 II Karlsson E., Delle U., Danielsson A., Parris T., Olsson B., Karlsson P., Helou K. High-resolution genomic profiling to predict 10-year survival in nodenegative breast cancer Manuscript, 2009 III Karlsson E., Delle U., Danielsson A., Olsson B., Abel F., Karlsson P., Helou K. Gene expression variation to predict 10-year survival in lymph-nodenegative breast cancer BMC Cancer, 2008;8(1):254 IV Karlsson E., Kov??cs A., Delle U., L?¶vgren K., Danielsson A., Parris T., Brennan D., Jirstr?¶m K., Karlsson P., Helou K. Up-regulation of cell cycle arrest protein BTG2 correlates with increased survival in breast cancer Manuscript, 2009

sahlgrenska.gu.se/